$400M under management. Small molecules, biologics, and cell therapy — research through proof-of-concept. The corporate venture arm of Taiho Pharmaceutical.
Plate 02 / Mandate
The legacy mandate, restated. Four axes — what we invest in, who it treats, how it is built, when we come in. Each axis is locked. We do not drift.
First-in-class drug discovery and the platforms that produce it. Spin-outs from the Taiho pipeline. Devices, diagnostics, and digital health on an opportunistic basis.
Oncology is the center of the page. We keep a deliberate, smaller seat for non-oncology work — immunology, allergy, bone, muscle, orphan — where the science is unusually good.
Three families, weighted equally. We do not have a house bias toward small molecule or biologic; we follow the science.
Research through proof-of-concept is most of what we do. Past the founding euphoria, before the Phase II answers are obvious. IND through PoC on an opportunistic basis.
Plate 03 / Portfolio
Most of these came to us in their second or third year — past the founding euphoria, before the answers were obvious. That is the moment we like best, and it is most of what we do.
F-Prime Capital · UBS Oncology Impact
MPM Capital · Novartis
Atlas Venture · Newpath Partners
DCVC Bio · Catalio Capital
Most of the companies on this page came to us in their second or third year — past the founding euphoria, before the answers were obvious. That is the moment we like best, and it is most of what we do.
Series A oncology rounds usually close on a thin stack of evidence and a thicker one of conviction; the work is helping a syndicate sort the two without flattening either. Ten years on, we measure the decade not by exits but by the partners we now call back first.
